SEC recommends to grant permission to Biocon to conduct phase 2 trial for Itolizumab
Subject Expert Committee of CDSCO recommends to grant permission to Biocon to conduct phase 2 clinical trial for Itolizumab for Injection (r-DNA origin) 100 mg per vial.